AR113248A1 - Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos - Google Patents

Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos

Info

Publication number
AR113248A1
AR113248A1 ARP180101986A ARP180101986A AR113248A1 AR 113248 A1 AR113248 A1 AR 113248A1 AR P180101986 A ARP180101986 A AR P180101986A AR P180101986 A ARP180101986 A AR P180101986A AR 113248 A1 AR113248 A1 AR 113248A1
Authority
AR
Argentina
Prior art keywords
active ingredient
biodegradable
kinetics
modulate
drugs
Prior art date
Application number
ARP180101986A
Other languages
English (en)
Inventor
Juliette Serindoux
Audrey Petit
Lea Pebrel
Adolfo Lpez-Noriega
Myriam Abbassi
Anthony Rech
Christophe Roberge
Jean-Manuel Cros
Original Assignee
Medincell
Christophe Roberge
Anthony Rech
Cros Jean Manuel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medincell, Christophe Roberge, Anthony Rech, Cros Jean Manuel filed Critical Medincell
Publication of AR113248A1 publication Critical patent/AR113248A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
    • C08L2205/025—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group containing two or more polymers of the same hierarchy C08L, and differing only in parameters such as density, comonomer content, molecular weight, structure
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/03—Polymer mixtures characterised by other features containing three or more polymers in a blend

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente provee una composición biodegradable para la administración de fármacos que comprende una mezcla de por lo menos dos copolímeros de bloques tomados entre copolímeros de tribloques y de dibloques que comprende: (a) un copolímero biodegradable de tribloques que tiene la fórmula: Aᵛ-Bʷ-Aˣ en donde A es un poliéster y B es polietilenglicol y v y x son entre 1 y 3.000 y w es entre 3 y 300 y v = x o v ¹ x; (b) un copolímero biodegradable de dibloques que tiene la fórmula: Cʸ-Aᶻ en donde A es un poliéster y C es un polietilenglicol de extremos protegidos e y y z son el número de unidades repetitivas con y = 2 a 250 y z = 1 a 3.000; en donde la proporción en peso entre (a) y (b) es entre 1:19 y 5:1; y para por lo menos uno de los copolímeros de acuerdo a (a) o (b) A es poli(e-caprolactona-co-lactida); y (c) por lo menos un ingrediente farmacéuticamente activo.
ARP180101986A 2017-07-17 2018-07-17 Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos AR113248A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762533370P 2017-07-17 2017-07-17

Publications (1)

Publication Number Publication Date
AR113248A1 true AR113248A1 (es) 2020-03-11

Family

ID=63047314

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP180101987A AR113096A1 (es) 2017-07-17 2018-07-17 Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos
ARP180101988A AR113097A1 (es) 2017-07-17 2018-07-17 Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos
ARP180101986A AR113248A1 (es) 2017-07-17 2018-07-17 Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP180101987A AR113096A1 (es) 2017-07-17 2018-07-17 Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos
ARP180101988A AR113097A1 (es) 2017-07-17 2018-07-17 Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos

Country Status (13)

Country Link
US (3) US11612563B2 (es)
EP (3) EP3655038A1 (es)
JP (3) JP7210816B6 (es)
KR (1) KR20200032719A (es)
CN (1) CN111107840A (es)
AR (3) AR113096A1 (es)
BR (1) BR112020001031A2 (es)
CA (1) CA3069787A1 (es)
EA (1) EA202090161A1 (es)
IL (1) IL271986B2 (es)
MX (1) MX2020000618A (es)
TW (3) TWI795422B (es)
WO (3) WO2019016236A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3655038A1 (en) * 2017-07-17 2020-05-27 Medincell Pharmaceutical composition
GB201900258D0 (en) 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
US11680107B2 (en) * 2019-03-22 2023-06-20 Taipei Medical University Hydrogel composition for drug delivery and uses thereof
KR20220062372A (ko) * 2019-09-13 2022-05-16 메딘셀 에스.에이. 약물 전달 제형
GB202010340D0 (en) 2020-07-06 2020-08-19 Medincell Pharmaceutical composition
EP4014963A1 (en) * 2020-12-16 2022-06-22 Medincell Pharmaceutical composition
US20240099964A1 (en) * 2020-12-16 2024-03-28 Medincell S.A. Methods and Compositions for the Prophylactic Treatment of SARS-CoV-2 virus (COVID-19)
GB202104224D0 (en) * 2021-03-25 2021-05-12 Medincell Pharmaceutical composition
EP4329727A1 (en) * 2021-04-30 2024-03-06 MedinCell S.A. New formulation
EP4380546A1 (en) 2021-08-05 2024-06-12 MedinCell S.A. Pharmaceutical composition

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113359A (en) 1995-04-13 1999-06-20 Univ Ben Gurion Polysaccharide drug delivery matrix and slow release pharmaceutical preparation containing it
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
CA2299393A1 (en) 1997-08-08 1999-02-18 Sung Wan Kim Injectable biodegradable block copolymer gels for use in drug delivery
US20020164374A1 (en) 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US7018645B1 (en) * 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US20020192286A1 (en) * 2001-03-27 2002-12-19 Macromed, Incorporated Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
IL151288A0 (en) 2001-08-27 2003-04-10 Yissum Res Dev Co Multi-component reverse thermo-sensitive polymeric systems
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US20030228366A1 (en) 2002-06-11 2003-12-11 Chung Shih Reconstitutable compositions of biodegradable block copolymers
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
US20080247987A1 (en) 2005-08-04 2008-10-09 Angiotech International Ag Block Copolymer Compositions and Uses Thereof
CN101400717B (zh) * 2006-03-09 2011-08-31 科洛普拉斯特公司 具有用于软组织再生的改进生物相容性的可降解亲水嵌段共聚物
ES2376175T3 (es) 2007-09-28 2012-03-09 Bind Biosciences, Inc. Direccionamiento a células de c�?ncer usando nanopart�?culas.
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
TWI388591B (zh) * 2008-03-28 2013-03-11 Ind Tech Res Inst 溫度敏感性材料
US7993666B2 (en) 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
SI2774608T1 (sl) 2008-06-16 2020-02-28 Pfizer Inc. Polimerni nanodelci, napolnjeni z zdravilom, ter postopki za njihovo pripravo in uporabo
US20100015049A1 (en) 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
EA201290497A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
WO2011079279A2 (en) 2009-12-23 2011-06-30 Board Of Trustees Of The University Of Illinois Nanoconjugates and nanoconjugate formulations
US20110319473A1 (en) 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
EA027046B1 (ru) * 2010-12-29 2017-06-30 Мединселл Биоразлагаемая композиция для доставки лекарственных средств, способ ее получения и ее применение
CN102058909A (zh) 2011-01-18 2011-05-18 复旦大学 聚乙二醇－共聚酯嵌段共聚物防粘连材料及其制备方法与应用
ES2820369T3 (es) 2011-03-31 2021-04-20 Ingell Tech Holding B V Composiciones biodegradables adecuadas para liberación controlada
WO2012131106A1 (en) * 2011-03-31 2012-10-04 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
EP2674167A1 (en) 2012-06-14 2013-12-18 PLS-Design GmbH Controlled activation of complement components for use as endogenous adjuvant
WO2014001905A1 (en) * 2012-06-27 2014-01-03 Medincell Biodegradable drug delivery for hydrophobic compositions
US8954932B2 (en) * 2012-12-11 2015-02-10 International Business Machines Corporation Crash notification between debuggers
EP2983716A4 (en) 2013-04-11 2017-01-25 Commonwealth Scientific and Industrial Research Organisation Composition for controlled delivery of bioactive agents
KR101512759B1 (ko) * 2013-08-30 2015-04-16 아주대학교산학협력단 이온성 작용기가 곁사슬 또는 말단에 도입된 온도감응성 폴리에틸렌글리콜/폴리에스터 블록 공중합체 및 이의 제조방법
CN103601878B (zh) * 2013-11-25 2015-05-13 沈阳药科大学 高稳定性聚乙二醇-聚酯聚合物及其应用
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
JP2017513950A (ja) 2014-04-18 2017-06-01 ファイザー・インク Ｋ−ｒａｓ変異を有するがんを処置するためのドセタキセルを含むナノ粒子
US10780175B2 (en) 2015-04-18 2020-09-22 The Texas A&M University System Polymer systems and their applications in diagnostics and drug delivery
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
WO2017044936A1 (en) 2015-09-11 2017-03-16 Pfizer Inc. Methods of controlling morphology of polymeric nanoparticles
PL3377041T3 (pl) * 2015-11-16 2024-03-11 Medincell S.A. Sposób morselizacji i/lub kierowania farmaceutycznie aktywnych składników do tkanki maziowej
US20170266187A1 (en) 2016-03-15 2017-09-21 Pfizer Inc. Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same
CN105878191B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 缓释微粒的制备方法、制得的缓释微粒及其应用
CN105963257B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN105878174B (zh) 2016-04-26 2021-06-29 广州帝奇医药技术有限公司 一种固体分散体及其制备方法与应用
CN105963258B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
EP3503877B8 (en) 2016-08-26 2022-04-20 SK Joint Ventures II, LLC Biodegradable polymer formulations for extended efficacy of botulinum toxin
EP3655038A1 (en) * 2017-07-17 2020-05-27 Medincell Pharmaceutical composition

Also Published As

Publication number Publication date
EP3655038A1 (en) 2020-05-27
EP3655017A1 (en) 2020-05-27
JP7210816B6 (ja) 2023-02-03
JP7205019B2 (ja) 2023-01-17
TWI795423B (zh) 2023-03-11
JP2020527586A (ja) 2020-09-10
KR20200032719A (ko) 2020-03-26
IL271986B2 (en) 2023-08-01
US20200179518A1 (en) 2020-06-11
JP2020527587A (ja) 2020-09-10
AR113097A1 (es) 2020-01-29
WO2019016233A1 (en) 2019-01-24
US20200171157A1 (en) 2020-06-04
TW201907956A (zh) 2019-03-01
IL271986B1 (en) 2023-04-01
WO2019016234A1 (en) 2019-01-24
MX2020000618A (es) 2020-09-28
WO2019016236A1 (en) 2019-01-24
EP3655037A1 (en) 2020-05-27
CA3069787A1 (en) 2019-01-24
AU2018304881A1 (en) 2020-01-30
US11801217B2 (en) 2023-10-31
TW201907954A (zh) 2019-03-01
JP7210816B2 (ja) 2023-01-24
TWI795422B (zh) 2023-03-11
TWI795421B (zh) 2023-03-11
TW201907955A (zh) 2019-03-01
US11666527B2 (en) 2023-06-06
JP7187738B2 (ja) 2022-12-13
JP7205019B6 (ja) 2023-02-03
CN111107840A (zh) 2020-05-05
US20200163873A1 (en) 2020-05-28
BR112020001031A2 (pt) 2020-07-14
US11612563B2 (en) 2023-03-28
AR113096A1 (es) 2020-01-29
IL271986A (en) 2020-02-27
EA202090161A1 (ru) 2020-06-29
JP2020527590A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
AR113248A1 (es) Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos
CY1119829T1 (el) Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου
WO2012131104A3 (en) Biodegradable compositions suitable for controlled release
MY196264A (en) Breathable Films with Microbial Barrier Properties
TN2014000520A1 (en) Biodegradable drug delivery for hydrophobic compositions
JP2015522001A5 (es)
ES2721850T3 (es) Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
AR088875A1 (es) Forma de dosis farmaceutica oral a prueba de manipulacion
AR038150A1 (es) Composicion termoplastica superabsorbente y articulo que la incluye
MX347056B (es) Composiciones farmaceuticas.
MX2013012934A (es) Nanoparticulas polimericas para el suministro de farmacos.
BR112014032895A2 (pt) composição apropriada para um artigo fabricado
DE60129838D1 (de) Orale pharmazeutische zusammensetzung mit einem blockcopolymer
CL2022002233A1 (es) Polímeros anfifílicos y su uso para mejorar la producción de nanopartículas para el suministro dirigido de antígenos
MX2018008868A (es) Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso.
ECSP18000689A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
BR112023019298A2 (pt) Composição farmacêutica
MX367884B (es) Copolimeros segmentados de poli(p-dioxanona-co-epsilon-caprolacton a) ricos en p-dioxanona para aplicaciones medicas y dispositivos elaborados a partir de estos.
ECSP17081071A (es) Composiciones de matriz polimérica tópicas que comprenden una alta concentración de hialuronato de sodio bio-fermentado y sus usos
CO2024001992A2 (es) Composiciones para el tratamiento de la vaginosis bacteriana
MX2022003246A (es) Composiciones de polimero liquido y sistemas para suministro prolongado de peptidos como ingredientes farmaceuticos activos.
AR126791A1 (es) Composición farmacéutica que comprende nanopartículas para la administración dirigida de antígenos
CL2018002346A1 (es) Composiciones poliméricas que minimizan la fijación de fosfato

Legal Events

Date Code Title Description
FB Suspension of granting procedure